Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334472 · ClinicalTrials.gov registry record
A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 105
- Enrollment target
NCT05334472 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT05334472 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.
Interventions
- OTHER Kesimpta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-11-24 |
| Est. Completion | 2023-02-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05334472
The ClinicalTrials.gov registry entry for NCT05334472 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kesimpta is the first listed.
NCT05334472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05334472 about?
NCT05334472 is a clinical study titled "A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis". This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA.
What is the current status of trial NCT05334472?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2021-11-24. Estimated completion is 2023-02-15.
What interventions are being tested in trial NCT05334472?
The interventions under investigation include: Kesimpta (OTHER).
Who is sponsoring clinical trial NCT05334472?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.